![]() ![]() Our research offers insights into reversing exhaustion markers, opening up avenues for more effective immunotherapeutic strategies.ģ️⃣ Chronic Viral Infections: Chronic viral infections, such as #hepatitis B and C, HIV/AIDS, and #herpes viruses, often lead to T cell exhaustion. By targeting the markers associated with exhaustion, we can enhance the immune response against #melanoma cells, potentially improving patient outcomes.Ģ️⃣ Lung Cancer: Immunotherapy has shown promise in treating lung cancer, but T cell exhaustion remains a major challenge. In addition to triple-negative #breastcancer, this groundbreaking #research on T cell exhaustion and immune rejuvenation holds great potential for addressing other challenging #diseases and conditions, including:ġ️⃣ Melanoma: T cell exhaustion is a significant barrier in the treatment of melanoma. Our recent whitepaper on T cell exhaustion and its reversal has wide ranging applications. View original content for more details, please visit: Treatment-related adverse events (TRAEs) were reported in 89.3% (25/28) patients, and Grade 3 TRAEs were reported in 39.3% (11/28) patients. (Cohort 2 recruited patients who failed previous anti-PD-(L)1 and anti-VEGF(R) treatments,11 patients). ![]() In Cohort 2, the ORR and DCR were 9.1% (18.2% per mRECIST) and 54.5%. (Cohort 1 recruited patients who failed previous anti-VEGFR multikinase inhibitor(s) treatment while have not received anti-PD-(L)1 treatment, 15 patients). In Cohort 1, the objective response rate (ORR) and disease control rate (DCR) were 46.7% and 73.3%. Toripalimab is the first monoclonal anti-PD-1 antibody approved by the China NMPA onto the market. Porustobart (HBM4003), an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody that generated from Harbour Mice®platform. Nice job and moving forward! HARBOUR BIOMED just reported (May 26, 2023) Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma (NCT05149027).
0 Comments
Leave a Reply. |